<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00483730</url>
  </required_header>
  <id_info>
    <org_study_id>AV-007-IM</org_study_id>
    <nct_id>NCT00483730</nct_id>
  </id_info>
  <brief_title>Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)</brief_title>
  <official_title>A Multi-centre, Double-blind, Placebo-controlled, Randomised, Parallel Group Clinical Trial to Evaluate Efficacy and Safety of Actovegin® in Diabetic Type 2 Patients With Symptomatic Diabetic Peripheral Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nycomed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nycomed</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess clinical efficacy and safety of Actovegin in type 2 diabetic patients with&#xD;
      symptomatic diabetic peripheral polyneuropathy after 250 ml i.v. infusions once daily for 20&#xD;
      days followed by oral treatment 600 mg × 3 daily for 140 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TSSaverage: Average of the TSS over the treatment period (AUC / exposure time) VPTaverage: Average of the VPT measurement over the treatment period (AUC / exposure time)</measure>
    <time_frame>Approx. 5½ months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIS-LLaverage: Average of the NIS-LL over the treatment period (AUC / exposure time)</measure>
    <time_frame>Approx. 5½ months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">569</enrollment>
  <condition>Symptomatic Diabetic Peripheral Polyneuropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deproteinised hemoderivative of calf blood (Actovegin)</intervention_name>
    <description>Symptomatic diabetic peripheral polyneuropathy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The medical condition / disease to be studied is symptomatic diabetic peripheral&#xD;
        polyneuropathy.&#xD;
&#xD;
        All inclusion criteria must be answered &quot;yes&quot; for a patient to participate in the trial.&#xD;
&#xD;
          1. Has the patient given informed consent according to local requirements before any&#xD;
             trial related activities? A trial related activity is any procedure that would not&#xD;
             have been performed during the routine management of the patient.&#xD;
&#xD;
          2. Is the patient aged ≥ 18 to ≤ 65 years?&#xD;
&#xD;
          3. Does the patient suffer from type 2 diabetes mellitus?&#xD;
&#xD;
          4. Has the patient evidence of symptomatic diabetic peripheral polyneuropathy, i.e. TSS ≥&#xD;
             6 and NIS-LL ≥ 2?&#xD;
&#xD;
          5. Is the patient's VPT measured to ≤ 30V?&#xD;
&#xD;
          6. Has the patient adequate circulation to the foot as evidenced by a palpable pulse on&#xD;
             posterior tibialis artery and dorsal artery of foot?&#xD;
&#xD;
          7. Is the HbA1C level less than 10%?&#xD;
&#xD;
          8. Is the patient able to make frequent clinic visits over the trial period?&#xD;
&#xD;
             For patients receiving tricyclic antidepressants, anticonvulsants, mexiletine or&#xD;
             neuroleptics as treatment of neuropathic pain:&#xD;
&#xD;
          9. Has the regimen been stable within the last month?&#xD;
&#xD;
             For female patients of childbearing potential (childbearing potential is considered&#xD;
             until menopause has lasted more than 12 months):&#xD;
&#xD;
         10. Does the patient use an acceptable contraceptive method (hormonal pills, patches,&#xD;
             implants, injections or intrauterine device)?&#xD;
&#xD;
         11. Is the pregnancy test negative before the 1st dose of trial medication?&#xD;
&#xD;
        (Surgically hysterectomised and surgically successfully sterilized females may be included&#xD;
        on the same conditions as male patients).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All exclusion criteria must be answered &quot;no&quot; for a patient to participate in the trial.&#xD;
&#xD;
          1. Does the patient suffer from known allergy towards Actovegin or similar preparations?&#xD;
&#xD;
          2. Has the patient asymmetrical neuropathy of the trunk or proximal lower limbs?&#xD;
&#xD;
          3. Does the patient suffer from diabetic foot ulceration or infections?&#xD;
&#xD;
          4. Does the patient suffer from diabetic amyotrophy?&#xD;
&#xD;
          5. Does the patient suffer from decompensated cardiac insufficiency, pulmonary oedema,&#xD;
             oliguria, anuria, generalised oedema?&#xD;
&#xD;
          6. Does the patient suffer from polyneuropathy due to other underlying causes?&#xD;
&#xD;
          7. Has the patient been hospitalised due to diabetic polyneuropathy within the last&#xD;
             month?&#xD;
&#xD;
          8. Has the patient participated in any other trial with an Investigational Medicinal&#xD;
             Product (IMP) or device within 30 days before inclusion in this trial?&#xD;
&#xD;
          9. Has the patient ever used medications that may be etiological factors for neuropathy,&#xD;
             such as isoniazid, nitrofurantoin, vincristine and phenytoin?&#xD;
&#xD;
         10. Has the patient used cerebrolysin or α-lipoic acid or received Transcutaneous Electric&#xD;
             Nerve Stimulation (TENS) or acupuncture within the last month?&#xD;
&#xD;
         11. Has the patient received opiates as treatment of his / her diabetic polyneuropathy&#xD;
             within the last month?&#xD;
&#xD;
         12. Does the patient suffer from any malignancy?&#xD;
&#xD;
         13. Is the patient nursing?&#xD;
&#xD;
         14. Does the patient suffer from any mental, psychiatric or other conditions that may&#xD;
             compromise data collection and understanding of written and verbal information given&#xD;
             in the trial?&#xD;
&#xD;
         15. Does the patient suffer from present and / or previous chronic alcohol abuse?&#xD;
&#xD;
         16. Is there any anamnestic evidence of hypothyroidism?&#xD;
&#xD;
         17. Is there any anamnestic evidence of vitamin B12 deficiency?&#xD;
&#xD;
         18. Does the patient suffer from an impaired renal function with high blood urea nitrogen&#xD;
             (BUN) and / or increased serum creatinine (&gt;120 µmol/L)?&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nycomced Clinical Trial Operations</last_name>
    <role>Study Chair</role>
    <affiliation>Headquaters</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nycomed</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>June 6, 2007</study_first_submitted>
  <study_first_submitted_qc>June 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2007</study_first_posted>
  <last_update_submitted>May 4, 2012</last_update_submitted>
  <last_update_submitted_qc>May 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <name_title>Nycomed</name_title>
    <organization>Nycomed</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Actovegin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

